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Abstract Butyric acid (BA) induces differentiation of human
leukemia, including HL-60 cells. By using a fluorescent probe,
we showed that reactive oxygen species (ROS) were generated in
BA-treated cells. BA-induced differentiation was accompanied
with an increased secretion of pro-matrix metalloproteinase
(MMP)-9. Both phenomena were inhibited by antioxidants.
Tissue inhibitors of MMP (TIMP)-1 and -2 secretion were
increased by BA, but differently affected by antioxidants. By
contrast, BA did not affect MMP-9 mRNA, and decreased
TIMP-1 and TIMP-2 mRNA levels. In addition, migratory and
invasive properties of HL-60 cells were enhanced by BA, but
differently affected by antioxidants. Altogether, these results
indicate that ROS are messengers of BA-induced differentiation
and increased invasiveness. ß 2002 Published by Elsevier Sci-
ence B.V. on behalf of the Federation of European Biochemical
Societies.
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1. Introduction
Di¡erentiation of leukemia cells has prompted increasing
research interest as an alternative or support to conventional
cytotoxic chemotherapy [1,2]. In addition to the well docu-
mented e¡ect of all-trans-retinoic acid (ATRA) [3,4], butyric
acid (BA) and derivatives appear as potential di¡erentiating
agents [2,5]. The di¡erentiation e¡ect of BA was clearly dem-
onstrated in the human K562 cell line, which was then com-
mitted to the erythroid pathway [6,7]. The human leukemia
cell line HL-60 represent a widely used model of acute mye-
loid leukemia type 2 [8], which can be committed toward
granulocytic or monocytic pathways when exposed to
ATRA or phorbol esters, respectively [9,10]. Di¡erentiation
of HL-60 cells can also be achieved with BA, even when dis-
crimination among granulocytic or monocytic pathways is
controversial [11]. Recently, several groups have shown that
ATRA- or phorbol ester-induced di¡erentiation of HL-60
cells is accompanied with changes in their matrix metallopro-
teinases (MMPs) expression [12^14].
MMPs are a family of zinc-dependent endopeptidases that
degrade all of the components of the extracellular matrix
[15,16]. MMP-2 and MMP-9 (gelatinases A and B), which
are secreted as the latent forms proMMP-2 and proMMP-9,
are the more frequently found in leukemia cells or cell lines
[17]. MMPs expression, secretion and activity are highly regu-
lated, particularly by a family of highly speci¢c inhibitor pro-
teins called tissue inhibitors of metalloproteinases (TIMPs)
[18]. Therefore, secretion of MMP-9 and/or MMP-2 was
thought to be involved in the invasive properties of malignant
cells [19], including leukemia [20]. Nevertheless, biological sig-
ni¢cance of MMPs and TIMPs expression is complex since
TIMPs could also have growth-promoting e¡ects and numer-
ous MMPs as well as other matrix-degrading enzymes could
be involved in the invasive process [15^19].
In spite of the well known biological and clinical impor-
tance of BA, the molecular mechanisms leading to BA-in-
duced cell growth regulation and di¡erentiation are poorly
understood. Besides, inhibition of histone deacetylase, stimu-
lation of protein phosphorylation, and the presence of buty-
rate responsive elements in BA-induced genes were thought to
be responsible for some of the biological e¡ects of BA [21^24].
We have previously shown the requirement of erythroid tran-
scription factors NF-E2 and GATA-1 [7,25] and the involve-
ment of reactive oxygen species (ROS) [26] in the case of BA-
triggered erythroid di¡erentiation of K562 cells. Then we hy-
pothesized that ROS would also be involved in the BA-trig-
gered molecular and cellular events in HL-60 cells, including
di¡erentiation, MMP expression and invasiveness.
First we aimed at evaluating the e¡ect of BA on MMP and
TIMP expression, and invasiveness of HL-60 cells. Our sec-
ond aim was to investigate the role of ROS in the di¡erentia-
tion induction, increased MMP-9 expression, and invasiveness
by using antioxidant molecules.
2. Materials and methods
2.1. Chemicals
Matrigel0, was purchased from BD Biosciences (Le Pont de Claix,
France). The £uorescent probe 6-carboxy-2P,7P-dichlorodihydro£uo-
rescein diacetate, di(acetoxymethyl ester) (C2938) was from Molecular
Probes (Eugene, OR, USA). BA, K-tocopherol (Vit E), N-acetylcys-
teine (NAC) and pyrrolidine dithiocarbamate (PDTC) were purchased
from Sigma (L’Isle d’Abeau Chesnes, France), and were prepared as
previously described [26], except NAC which was bu¡ered to pH 7.4
with sodium hydroxide.
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2.2. Cell culture
The human leukemia HL-60 cell line from the American Type Cul-
ture Collection (CCL-240) was maintained in RPMI 1640 medium
plus glutamax (Life Technologies, Saint Quentin en Yvelines, France)
supplemented with 15% heat-inactivated fetal calf serum (Life Tech-
nologies) under standard culture conditions. The presence of serum is
required for di¡erentiation induction in classical culture media but
interferes with MMPs determination (gelatin zymography and immu-
noassays). Therefore, for all experiments, serum-free cultures of ex-
ponentially growing cells were performed in UltraCULTURE0 me-
dium (BioWhittaker, Emerainville, France) supplemented with 2 mM
L-glutamine, which allow both di¡erentiation and MMP determina-
tion [27]. Cell number and viability were determined by the trypan
blue dye-exclusion method.
2.3. Di¡erentiation assay
After 3 days of treatment with 0.5 mM BA, and in the presence or
absence of antioxidants, the di¡erentiation of HL-60 cells was as-
sessed by nitroblue tetrazolium (NBT) dye reduction as described
previously [9,27]. Cells containing blue^black formazan granules, in-
dicative of the ability of HL-60 cells to generate superoxide anion
during a phorbol ester-induced respiratory burst, were scored as dif-
ferentiation positive. In addition, cytospin of control or BA-treated
cells were stained with Wright^Giemsa [10,27] and analyzed by mi-
croscopy to allow the observation of granulocytic features (i.e. multi-
lobular nucleus, prominent cellular indentation).
2.4. Spectro£uorimetric determination of ROS
Cells (1U106/ml) were treated with 0.5 mM BA for 30 min to 6 h,
washed, then incubated with 5 WM C2938 in RPMI 1640 without
phenol red (Sigma) for 30 min at 37‡C [28]. In some experiments
PDTC (1 WM) or Vit E (50 WM) was added 1 h before and during
BA treatment. After three washes, cells were resuspended in RPMI
1640 without phenol red and the £uorescence intensity was recorded
between 505 and 600 nm with an excitation wavelength of 495 nm.
The maximal emission wavelength was 520 nm.
2.5. Analysis of gene expression by reverse transcription-polymerase
chain reaction (RT-PCR)
Total RNAs were extracted by using TRIZOL0 reagent (Life Tech-
nologies) and 1 Wg was reverse-transcribed by using the reverse tran-
scription system from Promega (Charbonie'res, France). One tenth of
the resultant cDNAs was then ampli¢ed with recombinant Taq-DNA
polymerase (Life Technologies) as follows: 94‡C/90 s; then n cycles
consisting of 94‡C/30 s, Tm/60 s and 72‡C/60 s, and a ¢nal elongation
step of 72‡C/10 min. The primer sequences, Tm values, and number of
PCR cycles used were: MMP-9, sense GCGGAGATTGGGAAC-
CAGCTGTA, antisense GACGCGCCTGTGTACACCCACA, Tm
68‡C, n = 30; TIMP-1, sense TCAGGCTATCTGGGACCGCAGG-
GA, antisense ACCATGGCCCCCTTTGAGCCCCTG, Tm 68‡C,
n = 24 [29]; TIMP-2, sense CGAGAAACTCCTGCTTGGGG, anti-
sense CTCGGCAGTGTGTGGGGTC, Tm 68‡C, n = 27 [30]; GAP-
DH, sense CTCTGCCCCCTCTGCTGATGC, antisense CCAT-
CACGCCACAGTTTCCCG, Tm 60‡C, n = 23. The PCR products
were analyzed on a 1.4% agarose gel stained with ethidium bromide.
2.6. Gelatin zymography
Gelatinolytic activities were analyzed as described previously [27].
Brie£y, cell culture supernatants were harvested after 3 days of culture
in UltraCULTURE medium in the presence or absence of 0.5 mM
BA and/or antioxidants. Cellular extracts were then obtained after
lysis in 0.1 M Tris^HCl pH 8.1, 0.4% Triton X-100. An appropriate
volume of cell culture supernatant or cellular extract corresponding to
an equal amount of cells (1^5U103 cells) was applied to 10% SDS^
polyacrylamide gels containing 1 mg/ml gelatin. After migration, SDS
was removed by two incubations in 2% Triton X-100 during 30 min,
then gelatinases were activated by overnight incubation at 37‡C in 50
mM Tris^HCl pH 7.4, 0.2 M NaCl and 5 mM CaCl2. Proteolytic
activities were evidenced as clear bands against the blue background
of the Coomassie blue-stained gelatin.
2.7. Invasion and migration assay
In vitro invasion was determined in the Matrigel0-based assay as
described previously by Janiack et al. [31]. Brie£y, 13 mm polycar-
bonate ¢lters of 8 Wm pore size (Costar, Cambridge, MA, USA) were
coated with 50 Wg Matrigel. The lower compartments of the transwell
chambers were ¢lled with serum-free UltraCULTURE0 medium. Fol-
lowing indicated treatment, cells suspended in UltraCULTURE0 me-
dium were placed in the upper compartment (4U105 cells/chamber)
and incubated for 6 h at 37‡C, in 5% CO2. After incubation, cells that
had migrated through the Matrigel0-coated ¢lters were recovered
from the lower compartments and counted. The percentage of inva-
sion was calculated by considering the number of cells in the initial
cell suspension as 100%. To study cell migration, ¢lters were not
coated with Matrigel0 and the subsequent procedure was the same
as for the invasion assay. Each experiment was performed in triplicate
for each sample.
2.8. Enzyme-linked immunosorbent assay (ELISA)
Following indicated treatment, the MMP-9, TIMP-1 and TIMP-2
protein levels were quanti¢ed by ELISA (Biotrak1, Amersham-Bio-
sciences, Orsay, France) in conditioned media from 105 cells, accord-
ing to the manufacturer’s instructions.
2.9. Statistics
Results from at least three independent experiments were given as
mean þ S.D., and one-way analysis of variance (ANOVA) with Stu-
dent^Newman^Keuls post-hoc comparison was used for statistical
signi¢cance with P9 0.01.
3. Results and discussion
3.1. ROS production in BA-treated cells
In order to show ROS production, cells were treated with
0.5 mM BA for periods of time varying from 30 min to 6 h,
then incubated with the carboxy£uorescein derivative C2938,
the intracellular £uorescence of which is enhanced in the pres-
ence of ROS [28]. For each time point, the 520 nm £uores-
cence level was measured in control and BA-treated cells. The
ratio obviously indicates a ROS production in BA-treated
HL-60 cells, which was maximal for a 3 h treatment and
then declined (Fig. 1). In addition, the co-treatment of cells
with BA and either PDTC (1 WM) or Vit E (50 WM) antioxi-
dant inhibited the BA-induced ROS production (Fig. 1) indi-
cating that the £uorescence augmentation was related to ROS
Fig. 1. ROS production in BA-treated cells. HL-60 cells were
treated, or not, for the indicated time with 0.5 mM BA in the pres-
ence, or absence, of PDTC (1 WM) or Vit E (50 WM) before incuba-
tion with 5 WM of C2938 probe for 30 min. For each time point,
the £uorescence intensity was recorded by spectro£uorimetry (Vex,
495 nm; Vem, 520 nm) and results were expressed as the relative
£uorescence intensity (%) with respect to untreated cells. Results are
the mean of three independent experiments and S.D. were com-
prised between 10 and 20% of the value.
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production. According to the literature, the antioxidant NAC
has been avoided as it interfered with the £uorescence deter-
mination [28].
3.2. Inhibition of BA-induced di¡erentiation by antioxidants
An average of 60% of cells were induced to di¡erentiate
after 3 days of treatment with 0.5 mM of BA (Fig. 2). The
cytological observation of BA-treated cells after Wright^
Giemsa coloration con¢rmed the granulocytic di¡erentiation
of HL-60 cells (not shown). This di¡erentiation was accom-
panied with a marked inhibition of cell growth (59%) but no
cytotoxicity (s 95% of viable cells). As shown in Fig. 2, the
BA-induced di¡erentiation of HL-60 cells was strongly inhib-
ited by antioxidants. NAC (5 mM), PDTC (1 WM) and Vit E
(50 WM), which have no signi¢cant e¡ect on control cells,
diminished BA-induced di¡erentiation to an average of 17%
after 3 days of co-treatment (Fig. 2). It is important to notice
that antioxidants increased the cell growth inhibition to an
average of 70% and that higher concentrations of these com-
pounds became cytotoxic to HL-60 cells. These data con-
¢rmed that ROS are mediators of the BA-induced di¡erentia-
tion process in HL-60 cells, as previously suggested in the
erythroid K562 model [26].
3.3. MMP-9 expression was increased by BA and inhibited by
antioxidants
Untreated HL-60 cells have previously been described to
express mainly MMP-9 gelatinase activity [17]. Gelatin zy-
mography analysis of cell culture supernatants indicated that
proMMP-9 secretion was strongly increased by BA treatment
and inhibited in the presence of either NAC, PDTC or Vit E
(Fig. 3A). It should be noticed that both PDTC and Vit E
alone increased the proMMP-9 secretion in control cells. This
can explain the lower inhibition of BA-enhanced proMMP-9
secretion observed with PDTC or Vit E by contrast with the
NAC e¡ect (Fig. 3A). The ROS-mediated increase of
proMMP-9 in BA-treated cells was con¢rmed by the quanti-
¢cation of proMMP-9 in cell culture supernatants by ELISA
assay (Table 1). At the mRNA level, MMP-9 gene expression
remained unchanged after BA treatment, and antioxidants
were without signi¢cant e¡ect (Fig. 3B). Altogether, these
results support the role of ROS as mediators of BA-induced
increase of proMMP-9 secretion, but ruled out a transcrip-
tional e¡ect of BA.
Fig. 2. Inhibition of BA-induced di¡erentiation by antioxidants.
HL-60 cells were treated, or not (control), for 3 days with 0.5 nM
BA in the presence, or absence, of either 5 mM NAC, 1 WM
PDTC, or 50 WM Vit E. The percentage of di¡erentiation was as-
sessed by the NBT test. Data are the mean þ S.D. of ¢ve indepen-
dent experiments. Statistical signi¢cance was tested with one-way
ANOVA with post-hoc Student^Newman^Keuls comparison; col-
umns with di¡erent letters signi¢cantly di¡er from each other
(P6 0.01).
Fig. 3. BA increases (pro)MMP-9 secretion but not MMP-9 and
TIMPs mRNA levels. HL-60 cells were treated, or not (control), for
3 days with 0.5 mM BA in the presence, or absence, of either 5 mM
NAC, 1 WM PDTC, or 50 WM Vit E. Then culture media were har-
vested and total RNA extracted. A: Analysis of proMMP-9 secre-
tion by gelatin zymography of culture media. B: RT-PCR analysis
of MMP-9, TIMP-1 and TIMP-2 expression following indicated
treatments. Results from one experiment representative of three.
Table 1
Determination of proMMP-9 level in HL-60 cell cultures
Antioxidant treatment Level of proMMP-9 (ng/105 cells)a
Control BA
None 0.92 þ 0.52b 6.51 þ 2.48c
NAC 0.49 þ 0.39 1.36 þ 0.59d
PDTC 1.64 þ 0.66 4.29 þ 0.46d
aThe level of proMMP-9 secretion was determined by ELISA in
3 day culture supernatants of control and BA-treated HL-60 cells in
the presence or absence of antioxidant (NAC, 5 mM; PDTC, 1 WM).
bData are the mean þ S.D. of three independent experiments, each
done in triplicate.
cValue signi¢cantly di¡erent from the control according to one-way
ANOVA with Student^Newman^Keuls post-hoc comparison
(P6 0.01).
dValue signi¢cantly di¡erent from BA (P6 0.01).
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3.4. TIMP-1 and TIMP-2 secretion was increased by BA, but
di¡erently sensitive to antioxidants
TIMPs are the physiological inhibitors of MMPs activity
and their expression and/or secretion is thought to be coordi-
nated with MMP control. TIMP-1 and TIMP-2 levels were
therefore determined by ELISA assay in cell culture super-
natants. Results indicated that TIMP-1 secretion was mark-
edly increased in BA-treated cells with respect to control
cells and decreased in the presence of the antioxidant NAC
together with BA (Table 2). By contrast, the TIMP-2 level
was increased in a lesser extent and in a ROS-independent
way (Table 2). Surprisingly, RT-PCR analysis showed that
TIMP-1 and TIMP-2 mRNA steady-state levels were de-
creased in BA-treated cells (Fig. 3B). The TIMP-2 mRNA
level was insensitive to the presence of antioxidant in both
control and BA-treated cells. By contrast, the BA-induced
decrease of TIMP-1 mRNA level was inhibited by PDTC,
and in a lower extent by NAC (Fig. 3B). Altogether, these
results suggest the involvement of a complex regulation of
TIMP-1 and TIMP-2 by BA, combining transcriptional
down-regulation and post-transcriptional stimulation, and
both ROS-dependent and -independent events.
3.5. Cell migration and invasiveness were increased by BA
treatment
The above results suggest that BA is a modulator of the
migration and/or invasiveness capacity of HL-60 cells. We
used transwell ¢lters recovered, or not, by a Matrigel0 layer
to evaluate cell invasiveness or migration, respectively. As
shown in Fig. 4A, an average of 3% of control HL-60 cells
were able to cross the Matrigel0 layer and the ¢lter, this
percentage was increased to 21% for BA-treated cells. The
co-treatment with BA and antioxidant reduced the percentage
of invasive cells to an average of 14% and 9% with NAC or
Vit E, respectively (P6 0.01, Fig. 4A). This supports the in-
volvement of MMP-9, the secretion of which was ROS-depen-
dent. Furthermore, cell migration (i.e. in the absence of
Matrigel0), which is independent of matrix-degrading en-
zymes, was increased by BA treatment, but was una¡ected
in the presence of NAC or Vit E (Fig. 4B).
3.6. Conclusions
Our results show for the ¢rst time that BA-induced di¡er-
entiation was accompanied with an increase of the migratory
and invasive properties of HL-60 cells. Particularly, the extra-
cellular secretion of proMMP-9, TIMP-1 and TIMP-2 was
found increased in BA-treated HL-60 leukemia cells as previ-
ously observed in the colon cancer cell line SW1116 [32].
However, these authors show that cell invasiveness was inhib-
ited in BA-treated SW1116 cells [32]. This suggests that the
BA e¡ect is cell type-dependent, maybe according to the in-
vasive potential of the untreated cells, which was very low for
HL-60 cells (3%). Nevertheless, our results could not be at-
tributed to the classical transcriptional up-regulation often
seen with BA and mediated by histone deacetylase inhibition
[21], since mRNA levels for MMP-9 and TIMPs were found
unchanged or down-regulated, respectively. Besides, we have
shown that BA induces ROS production in the ¢rst hours of
treatment. Then, ROS were obviously involved in the BA-
induced di¡erentiation and proMMP-9 secretion, and, at least
in part, in the increased invasiveness of BA-treated HL-60
cells. By contrast, the inhibition of ROS synthesis by antiox-
idants did not signi¢cantly a¡ect the BA-enhanced migration
of HL-60 cells suggesting the stimulation of other signaling
pathways.
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Table 2
TIMP-1 and TIMP-2 levels in HL-60 cell cultures
Treatment TIMP-1 (ng/105 cells)a TIMP-2 (ng/105 cells)a
Control 4.07 þ 0.98b 2.33 þ 0.87
NAC 2.02 þ 0.92 2.17 þ 0.27
BA 44.39 þ 4.53c 4.51 þ 0.31c
BA+NAC 11.47 þ 5.31c;d 4.05 þ 0.38c
aThe levels of TIMP-1 and TIMP-2 were determined by ELISA in
3 day culture supernatants of control and BA-treated HL-60 cells in
the presence or absence of NAC (5 mM).
bData are the mean þ S.D. of three independent experiments, each
done in triplicate.
cValue signi¢cantly di¡erent from the control according to one-way
ANOVA with Student^Newman^Keuls post-hoc comparison
(P6 0.01).
dValue signi¢cantly di¡erent from BA (P6 0.01).
Fig. 4. BA increases HL-60 cells invasion and migration. HL-60
cells were treated, or not (control), for 3 days with 0.5 mM BA in
the presence, or absence, of 5 mM NAC or 50 WM Vit E. A: The
% of invasive cells was determined as the % of cells which have
crossed the Matrigel0-coated ¢lter after a 6 h incubation period.
B: The % of migrating cells was determined as previously with un-
coated ¢lters. Results are the mean þ S.D. of three independent ex-
periments, each done in triplicate. Statistical signi¢cance was tested
with one-way ANOVA with post-hoc Student^Newman^Keuls com-
parison; columns with di¡erent letters signi¢cantly di¡er from each
other (P6 0.01).
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